User Tools

Site Tools



Factor Xa inhibitors like edoxaban have been shown to have comparable or superior rates of stroke and systemic embolization prevention to warfarin while exhibiting lower clinically significant bleeding rates.

For both societal and payer perspectives, high-dose edoxaban with a price below the country cost-effectiveness threshold should be the first anticoagulant option for Thai patients with non-valvular atrial fibrillation and a high risk of bleedin 1).

Sivakumar et al. report a case of a man who presented with delayed, recurrent intracranial hemorrhage months after successful deep brain stimulator placement for Parkinson disease while on edoxaban for atrial fibrillation. Further reports on the use of novel anticoagulants after intracranial surgery are acutely needed to help assess the true relative risk they pose 2).

Rattanachotphanit T, Limwattananon C, Waleekhachonloet O, Limwattananon P, Sawanyawisuth K. Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding. Pharmacoeconomics. 2018 Nov 2. doi: 10.1007/s40273-018-0741-3. [Epub ahead of print] PubMed PMID: 30387074.
Sivakumar W, Garber ST, Schrock LE, House PA. Recurrent, delayed hemorrhage associated with edoxaban after deep brain stimulation lead placement. Case Rep Neurol Med. 2013;2013:691840. doi: 10.1155/2013/691840. Epub 2013 Jan 13. PubMed PMID: 23365773; PubMed Central PMCID: PMC3556834.
edoxaban.txt · Last modified: 2018/11/21 20:41 by administrador